Trial Profile

Dose reduction and discontinuation of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months randomised, open label, parallel-group, multi-centre trial

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 10 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Infliximab (Primary) ; Tocilizumab (Primary)
Indications Ankylosing spondylitis; Axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
Focus Therapeutic Use
Acronyms BIODOPT

03 Jun 2023 Results exploring tumour necrosis factor inhibitor drug levels during disease activity guided tapering in patients with inflammatory arthritis presented at the 24th Annual Congress of the European League Against Rheumatism
04 Jun 2022 Status changed from recruiting to active, no longer recruiting.
04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com